Daewoong Pharmaceutical Co., Ltd (KRX: 069620)

Market Cap	1.47T
Revenue (ttm)	1.40T
Net Income (ttm)	90.87B
Shares Out	11.51M
EPS (ttm)	7,897.50
PE Ratio	16.14
Forward PE	14.33
Dividend	600.00 (0.46%)
Ex-Dividend Date	n/a

Volume	49,296
Open	129,100
Previous Close	131,000
Day's Range	124,000 - 129,400
52-Week Range	100,100 - 164,400
Beta	0.82
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,710
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2023, Daewoong Pharmaceutical's revenue was 1.38 trillion, an increase of 7.44% compared to the previous year's 1.28 trillion. Earnings were 121.74 billion, an increase of 188.21%.